Factors associated with secondary non-depletion non-response to rituximab (2NDNR)
| Characteristics prior to rituximab retreatment | Continued to respond (n=61) | 2NDNR (n=9) | p Value |
| Concomitant IS, N (%) | 41 (67) | 2 (22) | 0.023 |
| Prednisolone, median (IQR) mg | 5 (0–10) | 5 (0–17.5) | 0.729 |
| Duration of response, median (IQR) weeks | 50 (36–107) | 62 (52–164) | 0.239 |
| Total BILAG score, median (IQR) | 16 (12–21) | 24 (12–27) | 0.209 |
| Partial clinical response in cycle 1, N (%) | 24 (39) | 3 (33) | 0.731 |
| Naïve B-cells, median (IQR) 109 cells/L | 0.0349 (0.0071–0.0735) | 0.0620 (0.0101–0.0950) | 0.296 |
| Memory B-cells, median (IQR) x 109/L | 0.0019 (0.0010–0.0047) | 0.0090 (0.0054–0.0394) | 0.175 |
| Plasmablasts, median (IQR) x 109/L | 0.0011 (0.0004–0.0036) | 0.0086 (0.0052–0.0227) | <0.001 |
*NDNR, secondary non-depletion and non-response; IS, immunosuppressant.